ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Standard Modifiable Cardiovascular Risk Factors and Prognostic Outcomes in Non-Valvular Atrial Fibrillation Patients on Oral Anticoagulants.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- "Left Atrial Appendage Closure Versus Medical Therapy in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".Journal of cardiovascular electrophysiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundStandard Modifiable Cardiovascular Risk Factors (SMurfs) influence Atrial fibrillation (AF). However, data on their cumulative prognostic effect in Asian non-valvular AF (NVAF) patients receiving oral anticoagulants (OACs) remain limited. This study investigated the association between the cumulative burden of SMurfs and the prognosis of these NVAF patients on oral anticoagulation (OAC) therapy.MethodsThis retrospective cohort study used Tianjin Health and Medical Data Platform (THMDP) data on 20 782 NVAF patients on OACs between 2015 and 2020. Patients were categorized into groups by the number of baseline SMurfs (0, 1-2, or 3-4: hypertension, diabetes, hyperlipidemia, smoking). Cox proportional hazards models assessed the association between SMurf burden group and the primary outcome (all-cause mortality) and secondary outcomes. Subgroup and sensitivity analyses were performed to evaluate the consistency and robustness of the findings.ResultsAfter adjusting for confounders, compared to the SMurf-less group, the hazard ratios (HRs) for all-cause mortality were 1.20 (95% confidence interval [CI]: 1.01-1.44) for the SMurf (1-2) group and 1.67 (95% CI: 1.33-2.08) for the SMurf (3-4) group. For ischemic stroke, the hazard ratio (HR) was 1.44 (95% CI: 1.03-1.99) for the SMurf (3-4) group, while the association was not significant for the SMurf (1-2) group. A more pronounced association between SMurfs and all-cause mortality was observed in patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.